Daily Roundup

IAG.ASX CCO.ASX BOL.ASX CMP.ASX ATX.ASX

Strong Sales Momentum Builds for Calmer Co, Compumedics Expands U.S. Reach, and Boom Logistics Investigates Former CEO

Calmer Co International Ltd (ASX: CCO) is reporting robust sales growth, with July sales reaching $715,000 and August delivering an impressive $838,000 - a 17% increase. This follows the company's successful pivot to a leaner, more efficient operating model in the second half of FY25. Notably, Amazon USA sales grew 12% month-on-month in August, fueled by the launch of new Taki Mai flavored kava shots. Subscriptions now represent 28% of sales, and organic search visibility has surged 674% year-over-year, reflecting strong brand loyalty.

Over at Compumedics Ltd (ASX: CMP), the company has received a significant boost with the FDA clearance of its Somfit®D single-use Home Sleep Testing device. This immediately doubles Compumedics' addressable U.S. market, providing access to an estimated $240 million annual market. The Somfit®D complements the company's reusable Somfit® device, creating an EEG-based platform that spans both single-use and reusable markets. Compumedics reaffirms its FY26 guidance of at least $70 million in revenues and $9 million in EBITDA.

In other news, Boom Logistics Ltd (ASX: BOL) has announced the resignation of former CEO and Managing Director, Mr. Ben Pieyre, following internal investigations that found evidence of personal and unauthorized use of company credit cards and funds. The amount of misuse is estimated to be less than $1 million, with $246,720 already recovered. Boom Logistics is conducting further investigations to determine the full extent of the misuse and will take appropriate action against Mr. Pieyre.

Amplia Therapeutics Ltd (ASX: ATX) has also made headlines, with the company enrolling and dosing the first patient in its new pancreatic cancer trial. The trial is exploring the combination of Amplia's FAK inhibitor narmafotinib with the FOLFIRINOX chemotherapy regimen, with sites in Australia and the U.S. participating.

Overall, it's been an eventful day for the Australian market, with a mix of positive sales updates, regulatory approvals, and corporate investigations. Stay tuned for more updates from these dynamic companies.